Difference between revisions of "Rosai-Dorfman-Destombes disease"
Jump to navigation
Jump to search
m |
|||
| Line 19: | Line 19: | ||
==Consensus guidelines== | ==Consensus guidelines== | ||
*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://pubmed.ncbi.nlm.nih.gov/29720485 PubMed] | *'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://pubmed.ncbi.nlm.nih.gov/29720485 PubMed] | ||
| − | |||
==[https://www.nccn.org NCCN]== | ==[https://www.nccn.org NCCN]== | ||
*[https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf NCCN Guidelines - Histiocytic Neoplasms] | *[https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf NCCN Guidelines - Histiocytic Neoplasms] | ||
| − | |||
=All lines of therapy= | =All lines of therapy= | ||
==Cobimetinib monotherapy {{#subobject:a6f6dd|Regimen=1}}== | ==Cobimetinib monotherapy {{#subobject:a6f6dd|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:#fecb7f|Variant=1}}=== | ===Regimen {{#subobject:#fecb7f|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
| Line 42: | Line 40: | ||
|} | |} | ||
''Note: there were N=2 patients with this type of histiocytosis.'' | ''Note: there were N=2 patients with this type of histiocytosis.'' | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21 | *[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21 | ||
| − | |||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://doi.org/10.1038/s41586-019-1012-y link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30867592 PubMed] NCT02649972 | # '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://doi.org/10.1038/s41586-019-1012-y link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30867592 PubMed] NCT02649972 | ||
| − | |||
[[Category:Rosai-Dorfman-Destombes disease regimens]] | [[Category:Rosai-Dorfman-Destombes disease regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Histiocytoses]] | [[Category:Histiocytoses]] | ||
Revision as of 23:42, 28 February 2023
| Section editor | |
|---|---|
 |
Gaurav Goyal, MD UAB Birmingham, AL  GauravGoyalMD
|
1 regimens on this page
1 variants on this page
|
Guidelines
Consensus guidelines
- 2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease PubMed
NCCN
All lines of therapy
Cobimetinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Diamond et al. 2019 (MSK 15-216) | 2016-NR | Phase 2, <20 pts in this arm (RT) |
Note: there were N=2 patients with this type of histiocytosis.
References
- MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02649972